JP2020523384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523384A5 JP2020523384A5 JP2019569364A JP2019569364A JP2020523384A5 JP 2020523384 A5 JP2020523384 A5 JP 2020523384A5 JP 2019569364 A JP2019569364 A JP 2019569364A JP 2019569364 A JP2019569364 A JP 2019569364A JP 2020523384 A5 JP2020523384 A5 JP 2020523384A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lymphoma
- seq
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 201000005171 Cystadenoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1709439.2 | 2017-06-14 | ||
| GB1709441.8 | 2017-06-14 | ||
| GBGB1709441.8A GB201709441D0 (en) | 2017-06-14 | 2017-06-14 | Dosage regime |
| GBGB1709439.2A GB201709439D0 (en) | 2017-06-14 | 2017-06-14 | Dosage regime |
| GBGB1710493.6A GB201710493D0 (en) | 2017-06-30 | 2017-06-30 | Dosage regime |
| GB1710493.6 | 2017-06-30 | ||
| GB1710496.9 | 2017-06-30 | ||
| GBGB1710496.9A GB201710496D0 (en) | 2017-06-30 | 2017-06-30 | Dosage regime |
| GBGB1720541.0A GB201720541D0 (en) | 2017-12-08 | 2017-12-08 | Dosage regime |
| GBGB1720544.4A GB201720544D0 (en) | 2017-12-08 | 2017-12-08 | Dosage regime |
| GB1720541.0 | 2017-12-08 | ||
| GB1720544.4 | 2017-12-08 | ||
| GBGB1803298.7A GB201803298D0 (en) | 2018-02-28 | 2018-02-28 | Dosage regime |
| GB1803298.7 | 2018-02-28 | ||
| PCT/EP2018/065862 WO2018229218A1 (en) | 2017-06-14 | 2018-06-14 | Dosage regimes for the administration of an anti-cd25 adc |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020523384A JP2020523384A (ja) | 2020-08-06 |
| JP2020523384A5 true JP2020523384A5 (enExample) | 2021-07-26 |
Family
ID=62636210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569364A Pending JP2020523384A (ja) | 2017-06-14 | 2018-06-14 | 抗ｃｄ２５ ａｄｃを投与するための投与レジメ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11426467B2 (enExample) |
| EP (1) | EP3638372A1 (enExample) |
| JP (1) | JP2020523384A (enExample) |
| KR (1) | KR20200028950A (enExample) |
| AU (1) | AU2018285455A1 (enExample) |
| BR (1) | BR112019026498A2 (enExample) |
| CA (1) | CA3064681A1 (enExample) |
| MX (1) | MX2019014923A (enExample) |
| WO (1) | WO2018229218A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3796942A1 (en) * | 2018-05-23 | 2021-03-31 | ADC Therapeutics SA | Molecular adjuvant |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| CA3142664A1 (en) * | 2019-06-10 | 2020-12-17 | Adc Therapeutics Sa | Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent |
| GB201917254D0 (en) * | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| WO2025051254A1 (zh) * | 2023-09-08 | 2025-03-13 | 信达生物制药(苏州)有限公司 | 半胱氨酸改造的抗体和免疫缀合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NZ540555A (en) | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| CA3052368A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors |
| EP2252246B1 (en) * | 2008-03-14 | 2014-06-18 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| PL2906251T3 (pl) | 2012-10-12 | 2018-02-28 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22 |
| WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057120A1 (en) * | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| MX364329B (es) * | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
| KR20150083856A (ko) | 2012-10-12 | 2015-07-20 | 에이디씨 테라퓨틱스 에스에이알엘 | 피롤로벤조디아제핀-항-her2 항체 컨주게이트 |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| DK2906253T3 (en) | 2012-10-12 | 2018-10-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine anti-PSMA antibody conjugates |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052533A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
| CN107148285B (zh) * | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| GB201506388D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506405D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506409D0 (en) | 2015-04-15 | 2015-05-27 | Williams David G And Berkel Patricius H C Van And Howard Philip W | Humanized anti-axl antibodies and their conjugates |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506394D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506393D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506399D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201507827D0 (en) | 2015-05-07 | 2015-06-17 | Adc Therapeutics Sarl | Diagnostic test |
| GB201513607D0 (en) * | 2015-07-31 | 2015-09-16 | Feingold Jay M | Pyrrolobenzodiazepine-antibody conjugates |
| IL257678B2 (en) * | 2015-08-25 | 2024-04-01 | Uab Res Found | Methods for stem cell transplantation |
-
2018
- 2018-06-14 KR KR1020207001219A patent/KR20200028950A/ko not_active Ceased
- 2018-06-14 CA CA3064681A patent/CA3064681A1/en active Pending
- 2018-06-14 EP EP18732040.3A patent/EP3638372A1/en not_active Withdrawn
- 2018-06-14 AU AU2018285455A patent/AU2018285455A1/en not_active Abandoned
- 2018-06-14 MX MX2019014923A patent/MX2019014923A/es unknown
- 2018-06-14 BR BR112019026498-1A patent/BR112019026498A2/pt not_active IP Right Cessation
- 2018-06-14 US US16/622,663 patent/US11426467B2/en active Active
- 2018-06-14 JP JP2019569364A patent/JP2020523384A/ja active Pending
- 2018-06-14 WO PCT/EP2018/065862 patent/WO2018229218A1/en not_active Ceased
-
2022
- 2022-07-15 US US17/812,950 patent/US20230039868A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523384A5 (enExample) | ||
| JP6628828B2 (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| JP2014533279A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2021502961A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2020524670A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2017526700A5 (enExample) | ||
| TR201808181T4 (tr) | Bir ıl-4r antagonist uygulanarak atopik dermatitin tedavi esilmesine yönelik yöntemler. | |
| HRP20180945T1 (hr) | Konjugati protutijelo-pirolobenzodiazepin | |
| JP2013517277A5 (enExample) | ||
| TW201919699A (zh) | 包含抗-cd38抗體及雷那度胺(lenalidomide)之組合物 | |
| JP6184952B2 (ja) | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| JP2019533682A5 (enExample) | ||
| JP2020502219A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| BR112013033916B1 (pt) | Uso de um anticorpo específico para cd19 | |
| JP2018515493A5 (enExample) | ||
| JP2016094424A5 (enExample) |